ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences in September:

• Wells Fargo Virtual Healthcare Conference
  
  Format: Presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1×1 meetings
  
  Date: Thursday, September 9, 2021
  
  Time: 12:00 – 12:30 p.m. ET
  
  
  
  23rd H.C. Wainwright & Co. Annual Global Investment Conference
  
  Format: On-demand presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1×1 meetings
  
  Date: Monday, September 13, 2021
  
  Time: 7:00 a.m. ET
  
  
  
  UBS Biotechnology Private Company Symposium
  
  Format: Presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1×1 meetings
  
  Date: Wednesday, September 22, 2021
  
  Time: 12:00 – 12:30 p.m. ET

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210903005275/en/